新辅助性免疫疗法用于周围耳膜皮肤状细胞癌
David Z Allen1, Neil Gross2, Marc-Elie Nader2
1Department of Otorhinolaryngology, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Head & neck
|October 25, 2025
概括
新辅助免疫疗法显著改善了晚期外耳皮肤状细胞癌 (pCSCC) 的存活率. 这种方法提高了与前期手术相比的无事件生存率和整体生存率.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 晚期外耳皮肤状细胞癌 (pCSCC) 的标准治疗包括手术和辅助辐射.
- 新辅助免疫疗法在可切除的pCSCC中显示出有希望的高病理反应率.
研究的目的:
- 评估新辅助免疫疗法对晚期可切除pCSCC患者的生存结果的影响.
- 为了比较接受新辅助免疫疗法并随后接受手术的患者和接受前期手术的患者之间的无事件生存率 (EFS) 和整体生存率 (OS).
主要方法:
- 在2005-2025年期间,对病理确认的pCSCC患者进行了治疗意图手术的回顾性审查.
- 在手术前接受新辅助免疫治疗的患者与接受了前期手术的患者的年龄和阶段匹配比较.
- 用于估计EFS和OS的Kaplan-Meier方法.
主要成果:
- 包括85名患者:24人 (28.2%) 接受了新辅助免疫疗法,61人 (71.7%) 接受了前期手术.
- 新辅助免疫治疗组的EFS (5.9与3.4年相比; p=0.02) 和OS (不满足与4.4年相比; p=0.031) 的中位数显著长.
- 两年EFS在新辅助组 (87%) 与前期手术组 (55%) 相比更高.
结论:
- 新辅助免疫疗法证明了对先进的可切除pCSCC的改善生存结果.
- 支持将这组患者纳入未来随机临床试验.
- 强调免疫疗法在管理先进的pCSCC方面的潜力.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Skin Cancer
5.7K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.7K


